fda bpc-157 category 2 compounding panel votes to place popular peptide on list Today, the FDA's Pharmacy Compounding

Here's a few reasons: Third-Party Lab Testing: Xcel Peptides gets every BPC-157 batch tested by an independent lab and posts the lab reports online

When used strategically, peptide protocols may help support optimization across multiple areas of health and performance

Inhibition of food iron absorption by coffee

The panel also voted to approve five other peptides: KPV, TB-500, MOTS-c, Epitalion, and Semax

CagriSema CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, co-administered once weekly and studied in Phase 3 trials for obesity and type 2 diabetes.

A combination therapy using cord blood mononuclear cells (CBMNCs) and umbilical cord MSCs showed greater improvements than single-cell therapy alone , with no serious safety concerns reported